Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 17;13(4):981.
doi: 10.3390/biomedicines13040981.

Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress

Affiliations
Review

Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress

Vlad Iova et al. Biomedicines. .

Abstract

Despite continuous research, cancer is still a leading cause of death worldwide; therefore, new methods of cancer management improvement are emerging. It is well known that in the pathophysiology of cancer, oxidative stress (OS) is a significant factor. Nevertheless, there is currently no quick or easy way to identify OS in cancer patients using blood tests. Currently, in cancer treatments, Pt(IV) complexes are preferred to Pt(II) complexes in terms of adverse effects, drug resistance, and administration methods. Intracellular reductants convert Pt(IV) complexes to their Pt(II) analogs, which are Pt compounds with anti-carcinogenic effects. Our aim was to find out if Pt(IV) complexes could be used to assess blood oxidative stress indicators and, consequently, monitor the development of cancer. In this review, we analyzed previous research using the PubMed and Google Scholar public databases to verify the potential use of Pt(IV) complexes in cancer management. We found that two main serum antioxidants, glutathione and ascorbic acid, which are easily measured using conventional methods, react favorably with Pt(IV) complexes. Our research results suggest Pt(IV) complexes as therapeutic anticancer drugs and potential diagnosis agents. However, further research must be conducted to verify this hypothesis.

Keywords: Pt(IV); anticancer prodrugs; ascorbic acid; cancer; glutathione; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Effects of physiological and pathological OS.
Figure 2
Figure 2
The structures of Pt anticancer drugs: (a) cisplatin; (b) tetrachloro(DL-trans-1,2-diaminocyclohexane)platinum(IV) or ormaplatin/tetraplatin; (c) cis,cis,trans-[Pt(i-PrNH2)2Cl2(OH)2] or iproplatin; (d) cis,cis,trans-[Pt(NH3)2Cl2(OH)2] or oxoplatin.
Figure 3
Figure 3
Pt(IV) intracellular reduction mechanism and properties given to the prodrugs by the type of ligands.
Figure 4
Figure 4
Second-order rate constants k′ as a function of pH at 25.0 °C and μ = 1.0 M for the reduction of cis,trans-[Pt(cbdca)(NH3)2Cl2] by GSH (adapted from [246]).
Figure 5
Figure 5
Reaction mechanism proposed for the reduction of cis, trans-[Pt(cbdca)(NH3)2Cl2] by GSH (adapted from [246]).

Similar articles

References

    1. Wu Z., Xia F., Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: A systematic analysis for the GBD 2021. J. Hematol. Oncol. 2024;17:119. doi: 10.1186/s13045-024-01640-8. - DOI - PMC - PubMed
    1. World Health Organization Global Cancer Burden Growing, Amidst Mounting Need for Services. Feb 1, 2024. [(accessed on 1 January 2025)]. Available online: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--a....
    1. Global Surg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery Global variation in postoperative mortality and complications after cancer surgery: A multicentre, prospective cohort study in 82 countries. Lancet. 2021;397:387–397. doi: 10.1016/S0140-6736(21)00001-5. - DOI - PMC - PubMed
    1. Corrie P.G. Cytotoxic chemotherapy: Clinical aspects. Medicine. 2008;36:24–28. doi: 10.1016/j.mpmed.2007.10.012. - DOI
    1. Wang K., Tepper J.E. Radiation therapy-associated toxicity: Etiology, management, and prevention. CA Cancer J. Clin. 2021;71:437–454. doi: 10.3322/caac.21689. - DOI - PubMed

LinkOut - more resources